Screening of nonpolyenic antifungal metabolites produced by clinical isolates of actinomycetes

• Published in: Canadian journal of microbiology Vol. 49; no. 11; p. 669
• Main Authors: Lemriss, S, Laurent, F, Couble, A, Casoli, E, Lancelin, J M, Saintpierre-Bonaccio, D, Rifai, S, Fassouane, A, Boiron, P
• Format: Journal Article
• Language: English
• Published: Canada 01-11-2003
• Subjects: Anti-Bacterial Agents - pharmacology; Antifungal Agents - pharmacology; Aspergillus - drug effects; Candida - drug effects; Drug Evaluation, Preclinical; Ergosterol; Gram-Negative Bacteria - drug effects; Gram-Positive Bacteria - drug effects; Humans; Microbial Sensitivity Tests; Mitosporic Fungi - drug effects; Polyenes - chemistry; Streptomyces - metabolism; Trichophyton - drug effects
• ISSN: 0008-4166
• DOI: 10.1139/w03-088

The purpose of this work was to screen clinical isolates of actinomycetes producing nonpolyenic antifungals. This choice was made to limit the problem of rediscovery of well-known antifungal families, especially polyenic antifungals. One hundred and ten strains were tested, using two diffusion methods and two test media, against three yeast species and three filamentous fungi. Among 54 strains (49%) showing antifungal activity, five strains belonging to the genus Streptomyces were active against all test organisms and appeared promising. These results indicate that clinical and environmental isolates of actinomycetes could be an interesting source of antifungal bioactive substances. The production of nonpolyenic antifungal substances by these five active isolates was investigated using several criteria: antibacterial activity, ergosterol inhibition, and UV-visible spectra of active extracts. One active strain responded to all three selection criteria and produced potentially nonpolyenic antifungal metabolites. This strain was retained for further investigation, in particular, purification, structure elucidation, and mechanism of action of the active product.